Table 2.
Characteristics of JIA patients who are seropositive and seronegative for anti-SARS-CoV-2.
| Parameter | IgA Anti-SARS-CoV-2 |
IgG Anti-SARS-CoV-2 |
||||||
|---|---|---|---|---|---|---|---|---|
| Positive (n = 6) | Negative (n = 56) | Z/RR (95%CI) | p | Positive (n = 3) | Negative (n = 59) | Z/RR (95%CI) | p | |
| JIA activity | ||||||||
| Age (years) | 11.0 (2–15) | 12.0 (2–18) | 0.5 | 0.61 | 4.0 (2–13) | 12.0 (2–18) | 1.4 | 0.17 |
| ESR (mm/h) | 16.0 (2.0–120.0) | 6.5 (2.0–86.0) | –1.3 | 0.19 | 7.0 (2.0–9.0) | 8.0 (2.0–120.0) | 0.7 | 0.48 |
| CRP (mg/dL) | 0.03 (0.0–1.97) | 0.0 (0.0–17.9) | –0.5 | 0.60 | 0.0 (0.0) | 0.0 (0.0–17.9) | 1.4 | 0.17 |
| JADAS 71 | 12.5 (3.0–36) | 4.0 (0.0–32.9) | –2.01 | 0.044 | 3.3 (2.0–5.0) | 5.0 (0.0–36.0) | 0.5 | 0.64 |
| Active joint number | 2.0 (0–25) | 1.0 (0–15) | –1.7 | 0.086 | 0.0 (0–2) | 1.0 (0.0–25.0) | 0.6 | 0.55 |
| PGA | 3.5 (2.0–6.0) | 2.0 (0.0–7.0) | –1.7 | 0.089 | 1.0 (1.0–2.0) | 2.0 (0.0–7.0) | 0.7 | 0.46 |
| PhGA | 2.5 (2.0–6.0) | 2.0 (0.0–18.6) | –1.4 | 0.15 | 2.0 (0.0–2.0) | 2.0 (0.0–18.6) | 0.6 | 0.55 |
| Therapy | ||||||||
| Biological DMARDs | 2 (33.3%) | 28 (50%) | 0.67 (0.2–2.1) | 0.67 | 0 (0) | 30 (50.8%) | (∞) | 0.24 |
| Methotrexate | 2 (33.3%) | 47 (83.9%) | 1.0 (0.2–6.8) | 1.0 | 2 (66.7%) | 46 (78.0%) | 0.9 (0.4–1.9) | 0.54 |
| Sulfasalazine | 2 (33.3%) | 12 (21.4%) | 1.6 (0.5–5.4) | 0.61 | 1 (33.3) | 13 (22.0%) | 1.5 (0.3–8.0) | 0.54 |
| Glucocorticoids | 1 (16.7%) | 15 (26.8%) | 0.6 (0.1–3.9) | 1.0 | 1 (33.3) | 15 (25.4%) | 1.3 (0.2–6.9) | 1.0 |
JIA, juvenile idiopathic arthritis; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; JADAS 71, juvenile arthritis disease activity score 71; PhGA, physician global assessment of disease activity; PGA, parent/patient assessment of overall well-being; DMARDs Disease-modifying antirheumatic drugs.